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, and 0157 or flagellar antigen of nine different H serogroups of E. coli: H2, H7, H8, H10, Hl , H12, H18, H19, and H25. All patients had antibodies against the native antigen and/or the LPS of E. coli 0157, but positive agglutination with H7 was observed only in one patient. In the VT-ELISA with plates coated with purified VT 1 or VT 2, antibody against VT 2 was observed in the sera of five of six patients examined, but none of the patients possessed VT 1 antibody. These results indicate that the causative pathogen in these eight hemolytic-uremic syndrome cases is likely to be VT-producing E. coli 0157. The passive hemagglutination assay described here is a very sensitive, simple, and rapid method. This assay is highly recommended for the serological diagnosis of VT-producing E. coli infections, particularly in patients infected by serogroup 0157 strains. Furthermore, the VT-ELISA is useful in studying the role of VT in hemolytic-uremic syndrome.
Hemolytic-uremic syndrome (HUS) is manifested by the sudden onset of hemolytic anemia, thrombocytopenia, and acute renal failure about 10 days after the appearance of diarrhea and abdominal cramps. Although various bacterial and viral agents had been reported as the causative pathogens (15), Karmali et al. (9) (10) (11) reported that a verotoxin (VT; Shiga-like toxin)-producing E. coli (VTEC) strain, 0157:H7, was detected frequently in the stools of patients with HUS. Since then, the correlation between HUS and VTEC has been well studied in America, Canada, and Europe (11, 12, 16, 17) . In Japan, the incidence of VTEC infection has been increasing since an outbreak of VTEC 0157:H7 infection at a kindergarten in 1990, but the correlation between HUS and VTEC has not been clearly demonstrated. The detection of VTEC in the stools of patients with HUS is the most definitive diagnostic criterion. It can sometimes be very difficult to detect VTEC, as the organism can be recovered from stools only for a short time after diarrhea. HUS appears about 1 week after the onset of diarrhea, at which time the pathogen usually has disappeared from the stool. Also, treatment with antibiotics has been started before HUS appears. On the other hand, HUS patients produce a high level of antibody response to the pathogen (13) , and two studies (1, 3) have exploited this observation in the serodiagnosis of HUS. We have also reported the development of both a passive hemagglutination (PHA) assay using formalinized sheep erythrocytes (FSRBC) sensitized with soluble native antigen or heat-treated antigen (lipopolysaccharide [LPS] ) of VTEC 0157 and a VT enzyme-linked immunosorbent assay (ELISA) (21) . In order to study the utility of these assays for the diagnosis of VTEC infection, we examined diarrheal patients in the outbreak which occurred at a kindergarten in 1990 and in three sporadic cases which occurred in 1991 and 1992. The PHA assay showed that 49 (74.2%) of 66 patients of the kindergarten outbreak and all of the sporadic case patients had antibodies to both or either the native antigen and the LPS of 0157. In addition, anti-VT 2 antibody detected by the VT-ELISA was observed in the sera of 17 patients from the outbreak. In this study, we further evaluated the utility of these assays for eight HUS patients in whom no pathogens were detected.
MATERIALS AND METHODS HUS patients. The eight HUS patients in this study were identified at six different hospitals from May 1990 to May 1993. All patients (A through H) are children 2 to 7 years old, as shown in Table 1 . All patients presented to medical clinics at the onset of gastrointestinal symptoms and were subsequently hospitalized about 1 week after the onset. The most common symptoms included abdominal cramps, bloody or watery diarrhea, and fever. Vomiting was observed in three patients (A, B, and E). Bacterial examinations of fecal specimens from these patients were carried out at the hospitals with sorbitol IPA-bile salt agar (Kyokutou Seiyaku, Tokyo, Japan) and other media. VTEC or other pathogens were not isolated from these stools.
One patient (D) was culture positive for E. coli 0128, but the isolate did not produce VT. Hematological investigations were also carried out at the hospitals. Most of the patients suffered from hemolytic anemia, thrombocytopenia, and acute renal failure. They were diagnosed as having classical HUS. Their hemoglobin levels were 5.8 to 8.4 g/dl; haptroglobin levels, 6.8 to 21.8 mg/ml; platelet counts, 0.9 x 10 to 4.8 x 10 per mm; blood urea nitrogen levels, 39 to 132 mg/dl; and creatinine levels, 1.2 to 4.5 mg/dl. PHA. The PHA test was done in a microwell plate with V-shaped wells (Greiner), as described previously (21) . The PHA titer of serum against each antigen was expressed as the maximum dilution that showed agglutination.
Treatment of patient serum with 2ME. To investigate the immunoglobulin class of the antibodies revealed by reactions in the PHA assay and VT-ELISA, positive sera of patients were treated with 2-mercaptoethanol (2ME) (6) . Serum samples (0.1 ml) from patients were diluted 10-fold in saline, and an equal volume of 0.2 M 2ME (Wako Pure Chemical Industries, Tokyo, Japan) was added. After incubation at 37°C for 1 h, 2 ml of cold acetone was added to remove the 2ME and precipitate the serum protein. The mixture was centrifuged, and the acetone was removed with an aspirator. After the acetone treatment was repeated once, the pellet was resolved in 0.1 ml of saline and subjected to the PHA assay and VT-ELISA.
VT-ELISA. As described previously (21) Furthermore, these antibodies were inactivated by treatment with 2ME.
PHA testing for antibodies against nine common VTEC H antigens showed that only one patient, case B, had antibodies against H7 at the acute phase. The PHA titer of serum samiples taken at 1 and 2 weeks after the onset of illness was 1:900. After 4 weeks, the titer was below 1:100. These antibodies were also inactivated by treatment with 2ME.
VT antibodies detected in patients' sera by VT-ELISA. In preliminary experiments, negative control sera diluted 100-fold gave an A405 of 0.62 to 3.11 in wells coated with VT 1 or VT 2 and an A405 of 0.24 to 0.35 in wells without antigens. Since the absorbance in both antigen-coated and uncoated wells with the 1,000-fold dilution of these sera was in the range of 0.01 to 0.04, this dilution was used in VT-ELISA. Six serum samples of from the eight HUS patients were tested for anti-VT antibody. As shown in Table 1 , ELISA readings for VT 2 showed that the absorbance of serum samples from patients ranged from 0.094 to 0.283. The sera from five patients in whom an absorbance of above 0.2 (cutoff value) was observed indicated the presence of anti-VT 2 antibody. Antibody against VT 2 was found mainly in serum samples taken within 3 weeks of the onset of illness. VT 2 antibody also tended to fall rapidly after the acute phase of the illness, although the serum sample from patient A taken 6 weeks after the onset of diarrhea still was positive for VT 2 antibody. These positive sera were also treated with 2ME, and nonspecific reactions showing an absorbance of >2.0 were observed in all samples tested. On the other hand, ELISA results for VT 1 showed absorbance of serum samples ranging from 0.075 to 0.186. None of the sera tested showed an absorbance higher than the cutoff value. However, a suspicious positive reaction was observed in two patients' sera (patients E out in 1991 showed that the incidence of HUS has been increasing since the occurrence of an outbreak of VTEC 0157:H7 infection at a kindergarten in 1990. Approximately 100 HUS cases per year have been confirmed, and about 76% of these presented in typical fashion. Among these cases, gastrointestinal symptoms were the first signs of the disorder. In 43% of those cases, the causative pathogen was identified. E. coli was isolated from 76% of those stool samples in which any pathogen was identified. However, only 14% of these pathogens were VTEC. It is difficult to detect VTEC or any other pathogens in many cases of HUS. In the eight HUS cases in this study, no enteropathogens were detected in seven patients. Although E. coli 0128 was isolated from one patient, this strain did not produce VT. Therefore, the development of other methods for the diagnosis of the causative pathogen in HUS is desirable.
In order to diagnose VTEC infections serologically, we previously developed a PHA assay for the detection of antibodies against native antigen, LPS, and the flagellar antigen of VTEC 0157:H7, and a VT-ELISA to detect VT 1 and VT 2. Since the utility of these assays was studied with serum samples from diarrheal patients infected with VTEC 0157:H7 (21), we further assessed the usefulness of these assays by examining eight HUS patients in whom the causative pathogen was not isolated. In addition, for the application of these assays to HUS, three predominant VTEC 0 serogroups (026, 0111, and 0128) and eight common H serogroups of E. coli (H2, H8, H10, H11, H12, H18, H19, and H25) were added to the study, because VTEC strains belonging to various 0 or H serogroups apart from 0157:H7 have been isolated from patients with HUS (10, 17) .
The results showed that all patients had antibodies against the native antigen and/or the LPS of E. coli 0157 in serum samples taken at the acute or convalescent stage of the illness, but none of the sera reacted with the 0 antigens of other VTEC serogroups, such as 026, 0111, and 0128. In the PHA test for the nine common H antigens, only one patient (B) had antibodies against H7 in acute-phase serum samples. In the VT-ELISA, antibodies against VT The PHA titers against 0157 native and LPS antigens varied widely in individual patients. However, most of the patients acquired significantly high levels of antibody to both antigens in the early stages of infection. The PHA titers tended to fall rapidly after the acute phase of the disease, but they could sometimes be detected even 10 weeks after the onset of the illness. Similar trends in the antibody level of patients with HUS were observed in other studies (1, 3) . Bitzan and Karch (1) indicated that this rapid fall in antibody titer to the E. coli 0157 LPS may be due to the short half-life of immunoglobulin M (IgM). To study the immunoglobulin class related to positive reactions in the PHA assay and VT-ELISA, positive sera of HUS patients were treated with 2ME because IgM in serum is segregated from the 19S to the 6.5S subunit by reduction through a sulfhydrate reagent such as 2ME (6) . IgM antibody treated with 2ME becomes nonreactive. The treatment of the antibodies with 2ME in this study suggested that the immunoglobulin class of the antibodies detected in the PHA assay and VT-ELISA is IgM.
By using the VT-ELISA, an antibody response to VT 2 was observed in five of six patients' sera. This result indicates that VT-ELISA is useful as one method for the serodiagnosis of VTEC infection. Karmali et al. (11) reported that 4 of 15 cases of sporadic HUS and 2 patients with uncomplicated diarrhea who were siblings of HUS patients had neutralizing antibodies against the VT by Vero cell assay. VT-ELISA is highly sensitive and more convenient than the Vero cell assay to detect neutralizing antibody, but the usefulness of the VT-ELISA as a diagnostic tool may be limited to the general laboratory with access to pure VT. However, the VT-ELISA can be used to examine experimental verotoxemia in rabbits, monkeys, or other animals and to clarify the serological factors involved in HUS.
In the VT 1-ELISA, a suspicious positive reaction was observed in the serum samples from two patients. Although we used anti-human total immunoglobulin antiserum as a secondary antibody, the use of fractionated immunoglobulin antiserum may increase the specificity of the VT-ELISA.
In recent work reporting on the antibody against VT (2), a non-specific neutralizing effect of normal human sera against VT 2 and the non-IgG fraction was noted, suggesting the prcsenre of a VT 2 inhibitor. In VT-ELISA, a nonspecific reaction was also observed in some serum samples from healthy individuals when the samples were diluted 100-fold. This reaction could be excluded by a higher dilution (1,000-fold) of serum. However, it is unclear whether these nonspecific reactions are caused by some factor(s) in normal human sera. As one possibility, globotriosyl ceramide, one of the plasma-bound glycolipids, may be involved in these reactions. It has been consistently extracted from normal human plasma and recognized as a receptor of VT(s) (14) .
The PHA assay described here is simple to perform and was sensitive enough to detect antibodies against VTEC in patients with HUS. We highly recommend the PHA assay for the serological diagnosis of VTEC infections caused mainly by serogroup 0157. This assay is basically the same as that described by Bitzan and Karch (1), except for the use of FSRBC; however, the sensitized FSRBC are stable for 6 months at 5°C, the PHA can be performed immediately after the serum samples are obtained, and the results are available in 2 to 3 h. Furthermore, the VT-ELISA can be used to examine the VT in HUS and to study the role of VT in HUS.
